Business
Frequency Therapeutics to Present Business and Pipeline Overview at the 38th Annual J.P. Morgan Healthcare Conference
WOBURN, Mass.--(BUSINESS WIRE)-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate
About this update from Korro Bio, Inc.
[{"type":"text","content":" WOBURN, Mass.--(BUSINESS WIRE)--\n Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage\n biotechnology company focused on harnessing the body’s innate biology to\n repair or reverse damage caused by a broad range of degenerative\n diseases, today announced that Chief Executive Officer David L. Lucchino\n will present a Company overview at the 38th annual J.P.\n Morgan Healthcare conference.\n \n \n Mr. Lucchino’s presentation will take place on Wednesday, January 15th\n at 11 a.m. PT (2 p.m. ET) in the Elizabethan A room at the Westin St.\n Francis Hotel in San Francisco. The presentation will be followed by a\n question and answer session to be held in the Sussex room at 11:30 a.m.\n PT (2:30 p.m. ET). A live webcast of the both the presentation and the\n breakout session can be accessed on the investors section of the\n Frequency’s website, investors.frequencytx.com,\n or by linking here.\n A replay of the presentation will be posted on the Frequency website\n following the event.\n \n \n About Frequency Therapeutics\n \n \n Frequency Therapeutics is a leader in the development of medicines\n designed to activate progenitor cells within the body to treat\n degenerative diseases. The Company’s progenitor cell activation (PCA)\n approach stimulates progenitor cells to create functional tissue with\n the aim of developing disease modifying therapies. The Company’s lead\n product candidate, FX-322, is designed to regenerate auditory hair cells\n to restore hearing function. In a FX-322 Phase 1/2 study, statistically\n significant and clinically meaningful improvements in key measures of\n hearing function in patients with sensorineural hearing loss were\n observed. The Company also is evaluating additional diseases where its\n PCA approach could create functional tissue, including a development\n program in multiple sclerosis.\n \n \n Headquartered in Woburn, Mass., Frequency has a license and\n collaboration agreement with Astellas Pharma Inc. for FX-322, for which\n it retains U.S. rights, as well as additional collaboration and\n licensing agreements with academic and nonprofit research organizations\n including The Scripps Research Institute, Massachusetts Eye and Ear,\n Partners Healthcare and the Massachusetts Institute of Technology. For\n more information, visit www.frequencytx.com\n and follow Frequency on Twit...